Ontario source: bounded use
Breast cancer pathway map supplies a Canadian implementation example for this summary. It must not be presented as the rule outside Ontario.
sources for this section:Ontario breast pathway
Source-attributed clinical priorities
- Assess a new mass with breast and nodal examination and document skin, nipple and inflammatory features.
- Use age- and presentation-appropriate diagnostic imaging and tissue assessment through the provincial breast pathway.
- Refer rapidly for suspicious mass, pathologic nipple discharge, inflammatory change, skin tethering or concerning nodes.
- Triple assessment integrates clinical examination, imaging and tissue diagnosis when a lesion is suspicious.
sources for this section:Ontario breast pathway
Practical assessment and management workflow
1
Document duration, cycle relation, pregnancy, lactation, family history, prior imaging and systemic symptoms.
2
Examine both breasts and regional nodes and note skin, nipple, fixation and inflammatory changes.
3
Order age- and presentation-appropriate diagnostic imaging through the provincial breast service.
4
Ensure imaging-pathology concordance and track the referral rather than reassuring from one component alone.
sources for this section:Ontario breast pathway
Safety, red flags and urgent escalation
- Rapid inflammatory change, skin edema, ulceration or suspicious nodes requires expedited cancer assessment.
- A persistent mass needs evaluation even when initial imaging is reported benign if findings are discordant.
- Breast infection that does not improve as expected requires reassessment for abscess or malignancy.
sources for this section:Ontario breast pathway
Confirm the local pathway before acting
Ontario is used as an explicit Canadian implementation example, not as a national rule. Verify the equivalent pathway, formulary and escalation route in the patient鈥檚 province or territory.
sources for this section:Ontario breast pathway
Source and implementation boundary
Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:Ontario breast pathway
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- Ontario Health (Cancer Care Ontario)Breast cancer pathway mapaccessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Canada question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.